Gelonghui, January 17, 丨 While receiving research from institutional investors, Ge Longhui (688480.SH) recently said that Zijin Pharmaceutical currently accounts for less than 30% of domestic sales, and the market is mainly overseas. At present, the domestic market is relatively saturated, and overseas markets can increase their own market share by competing with BASF and others through product cost advantages and service advantages. Zijin Pharmaceuticals accounts for a relatively low sales volume in the Chilean market, mainly in the Democratic Republic of the Congo (DRC), and accounts for about 1/2 of Zijin Pharmaceuticals' current revenue.
赛恩斯(688480.SH)：紫金药剂目前国内销售占不到30%，市场主要在海外
Syns (688480.SH): Zijin Pharmaceutical currently accounts for less than 30% of domestic sales, and the market is mainly overseas
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.